A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV
Phase of Trial: Phase IV
Latest Information Update: 07 Jul 2015
At a glance
- Drugs Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms VALOR-HCV
- Sponsors Gilead Sciences
- 02 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Dec 2014 Planned End Date changed from 1 Feb 2015 to 1 Jun 2015 as reported against ClinicalTrials.gov record.
- 29 Dec 2014 Planned primary completion date changed from 1 Apr 2015 to 1 Jun 2015 as reported against ClinicalTrials.gov record.